HAUPTMENÜ
AWARDS
Forschergeist gefragt: 14. Novartis Oppenheim-Förderpreis für MS-Forschung ausgelobt
FernstudiumCheck Award: Deutschlands beliebteste Fernhochschule bleibt die SRH Fernhochschule
Vergabe der Wissenschaftspreise der Deutschen Hochdruckliga und der Deutschen Hypertoniestiftung
Den Patientenwillen auf der Intensivstation im Blick: Dr. Anna-Henrikje Seidlein…
Wissenschaft mit Auszeichnung: Herausragende Nachwuchsforscher auf der Jahrestagung der Deutschen…
VERANSTALTUNGEN
Wichtigster Kongress für Lungen- und Beatmungsmedizin ist erfolgreich gestartet
Virtuelle DGHO-Frühjahrstagungsreihe am 22.03. / 29.03. / 26.04.2023: Herausforderungen in…
Pneumologie-Kongress vom 29. März bis 1. April im Congress Center…
Die Hot Topics der Hirnforschung auf dem DGKN-Kongress für Klinische…
Deutscher Schmerz- und Palliativtag 2023 startet am 14.3.
DOC-CHECK LOGIN
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP)
12-15 March 2012
London, UK (March 16, 2012) – This page lists the opinions adopted at the March 2012 meeting of the Committee for Medicinal Products for Human Use (CHMP) and other important outcomes.
The new format allows users to view the main opinions adopted at the meeting, along with information on referral procedures, in a clear tabular format. Users can click on the links within the page to read individual press releases and more detailed information about the opinions.
The new format replaces the two PDF documents that used to list each meeting’s outcome: the CHMP meeting highlights, published on the Friday following the meeting and the CHMP monthly report, published around a week later. The Agency will publish a new page following each month’s CHMP meeting.
The Agency has gathered feedback from journalists and other stakeholders. It will make some changes to the format by April 2012.
Positive opinions on generics
Name of medicine |
INN |
Marketing authorisation applicant |
docetaxel |
Accord Healthcare Ltd |
|
docetaxel |
Fresenius Kabi Oncology Plc |
|
zoledronic acid |
Teva Pharma B.V. |
|
zoledronic acid |
Teva Pharma B.V. |
Positive opinions on extensions of therapeutic indications
Name of medicine |
INN |
Marketing authorisation holder |
meningococcal group A, C, W135 and Y conjugate vaccine |
Novartis Vaccines and Diagnostics S. r.l. |
|
measles, mumps, rubella and varicella vaccine |
Sanofi Pasteur MSD |
Final opinion on other variations
Name of medicine |
INN |
Marketing authorisation holder |
Helixate NexGen / Kogenate Bayer |
octocog alfa |
Bayer Pharma AG |
Final opinions on harmonisation referrals
Name of medicine |
INN |
Marketing authorisation holder |
letrozole |
Novartis group of companies |
|
live attenuated measles, mumps and rubella virus |
GSK group of companies |
Final opinions on safety reviews of centrally authorised medicines
Name of medicine |
INN |
Marketing authorisation holder |
strontium ranelate |
Les Laboratoires Servier |
Final opinions on reviews of centrally authorised medicines related to manufacturing issues
Name of medicine |
Medicines manufactured at Ben Venue Laboratories |
Other updates
Opinions on annual re-assessments and renewals |
Opinions on safety variations |
Medicines granted a Community marketing authorisation under the centralised procedure since the January CHMP meeting |
Guidelines and concept papers adopted during the March 2012 CHMP meeting |
European Union recommendations for virus strains in seasonal influenza vaccines 2012-2013 |
Quelle: European Medicines Agency, 16.03.2012 (tB).